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Abstract
Polycystic ovary syndrome (PCOS) is the most common cause of chronic anovulation and hyperandrogenism in
young women. Excessive ovarian production of Anti-Müllerian Hormone, secreted by growing follicles in excess, is
now considered as an important feature of PCOS. The aim of this review is first to update the current knowledge
about the role of AMH in the pathophysiology of PCOS. Then, this review will discuss the improvement that serum
AMH assay brings in the diagnosis of PCOS. Last, this review will explain the utility of serum AMH assay in the
management of infertility in women with PCOS and its utility as a marker of treatment efficiency on PCOS
symptoms. It must be emphasized however that the lack of an international standard for the serum AMH assay,
mainly because of technical issues, makes it difficult to define consensual thresholds, and thus impairs the
widespread use of this new ovarian marker. Hopefully, this should soon improve.
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Background
Polycystic ovary syndrome (PCOS) is the most common
cause of chronic anovulation and hyperandrogenism in
young women and affects 5 to 10 % of the female popu-
lation. Since 2003, the Rotterdam Consensus defines
PCOS and considers the antral follicle count (AFC) on
ultrasound as one of the diagnostic criteria. With the
improvement in ultrasonographic technology, the num-
ber of follicles seen on ultrasound increases almost daily
but remains dependent on the specific equipment.
Serum AMH is synthetized by small antral follicles,
which are precisely the ones seen on ultrasound. Serum
AMH could therefore be used as a surrogate for the
AFC in the diagnosis of PCOS. Serum AMH has also
demonstrated its utility in the treatment of infertility.
But the absence of an international standard for serum
AMH assay and the inability to define thresholds makes
application of serum AMH more difficult. The purpose
of this review is to explain the relationship between
AMH and PCOS and to describe the utility of serum
AMH in the diagnosis and treatment of PCOS.
AMH: from physiology to ovarian assessment
Physiology of AMH
AMH was only isolated and purified in 1984. Genes for
AMH and its receptor were sequenced and cloned in
1986 and 1994 respectively [1]. AMH has been predom-
inantly known for its role in male sexual differentiation
[2]. In women, AMH expression is restricted to one cell
type: the granulosa cells of the ovary. It starts around
the 25th week of gestation continuing until menopause
[1, 3]. AMH is expressed at all steps of folliculogenesis.
It is initiated as soon as primordial follicles are recruited
to grow into small preantral follicles and its highest ex-
pression is observed in pre antral and small antral folli-
cles. AMH expression then decreases with the selection
of follicles for dominance and is no longer expressed
during the FSH dependent stages of follicular growth
(except in the cumulus cells of pre ovulatory follicles), or
in atretic follicles [4, 5] (Fig. 1).
The functional role of AMH in early follicular growth
has been characterized by the study of “knocked out”
models for the AMH gene (AMHKO) [5, 8–10]. When
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there is no AMH, primordial follicles are recruited faster,
resulting in more growing follicles until the exhaustion
of primary follicle pool at younger age than wild-type
animals. AMH therefore has an inhibitory effect on early
follicular recruitment preventing the entry of primordial
follicles into the growing pool and thus premature ex-
haustion of follicles/oocytes [11]. AMH also has an in-
hibitory effect on cyclic follicular recruitment in vivo by
reducing the follicle sensitivity to FSH. In vitro AMH in-
hibits FSH induced pre antral follicle growth [4, 5, 8, 9].
AMH also reduces the number of LH receptors in
granulosa cells, also an FSH induced process [12]. Thus,
it is clear that AMH is involved in the regulation of fol-
licle growth initiation and in the threshold for follicle
FSH sensitivity.
AMH assay
In clinical application, AMH presents many opportun-
ities but unfortunately there are difficulties due to sev-
eral biological features of this molecule [13]. First, there
is a molecular heterogeneity of the circulating AMH
level with a non-cleaved biologically inactive form and a
cleaved biologically active form [14, 15]. Also, there is
variable sensitivity of the immunoassays to interference
by complement C1q and C3 [16]. Then, the stability of
AMH samples during the storage is not well known
[17]. Moreover, AMH concentration varies according to
the situation: in adults they are low (from 10.7 to 98
pmol/L) whereas in male new-borns they are very high
(749 to 1930 pmol/L) [13]. Measurement thus involves
different assays with different sensitivities. The last but
not the least technical problem is the inter-laboratory
variability, mainly for low values of serum AMH. The
difficulty lies in the fact there are currently different
ELISA immunoassays used worldwide: the Gen II
(Beckman Coulter), the EIA AMH/MHS kits (IOT or
“Immunotech” Beckman Coulter) and the AL-105-i
(Anshlabs), which use different monoclonal antibody
and different standards [18]. The lack of agreement
between these assays explains the absence of consen-
sual reference values and decision thresholds between
teams in the literature [11]. To maximize the clinical
utility of serum AMH measurement, current progress
has been made: development of an ultrasensitive essay
(‘pico AMH’ kit, Anshlabs), and automation on
immuno-analyzers (Access Dxi automatic analyzer,
Beckman Coulter. Cobas e instrument, Roche Diag-
nostics) allowing nearly identical values [19, 20]. Now
that AMH assay has been automated, it is with great
anticipation that an international standard for serum
AMH will be developed.
AMH as indicator of ovarian reserve and follicle growth
The ovarian reserve refers to the number of primordial
follicles, defined at birth (around 1 million). This follicu-
lar capital decreases gradually throughout reproductive
Fig. 1 Schematic model of AMH actions in the ovary. Dewailly, D., et al., Hum Reprod Update, 2014 [24]. AMH, produced by the granulosa cells of
small growing follicles, inhibits initial follicle recruitment and FSH-dependent growth and selection of pre antral and small antral follicles. In
addition, AMH remains highly expressed in cumulus cells of mature follicles. The inset shows in more detail the inhibitory effect of AMH on FSH-
induced CYP19a1 expression leading to reduced estradiol (E2) levels, and the inhibitory effect of E2 itself on AMH expression. T, testosterone;
Cyp19a1, aromatase. Figure modified from van Houten et al. (2010)
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life, with the continuous initiation of growth of some
follicles, and then mostly their apoptosis. There are
about 400 000 follicles in adolescents’ ovaries (leading
roughly to 400 ovulations), whereas only a thousand re-
mains at the time of Menopause.
Serum AMH concentration is strongly correlated with
the number of growing follicles since it represents AMH
secretion from all developing follicles [21, 22]. Consider-
ing that the rate of initiation of follicle growth is deeply
related to the initial follicular pool, we can assume that
serum AMH is an indirect reflection of ovarian reserve.
There is actually a very good correlation between serum
AMH levels and ultrasonographic measure of the antral
follicular count (AFC) [23, 24]. This can be explained
because circulating AMH is mostly produced by granu-
losa cells of follicles from 2 to 9 mm in diameter (60 %),
and those small follicles are precisely the ones counted
on the ultrasound when the AFC is done [25]. Measure-
ment of serum AMH is even more sensitive and specific
than the AFC as it also reflects pre antral and small an-
tral follicles (<2 mm), which are hardly seen in ultra-
sound. Serum AMH is therefore a deeper “probe” for
the growing follicular pool than the AFC [6].
Serum AMH assay has many benefits over the other
markers of ovarian reserve [11]. First, its plasmatic level
is quite stable from one cycle to another and throughout
the same cycle since the dominant follicle and corpus
luteum do not secrete AMH [26, 27]. Conversely, the
AFC and the FSH E2 pair have to be measured on the
first 5 days of the cycle [28–30]. Also, a recent study has
shown ethnicity does not influence serum AMH level,
contrary to previous studies [31]. Besides its minor vari-
ability, serum AMH is also useful when the AFC cannot
be done such as in obese, virgin or poorly echogenic pa-
tients [6]. Moreover, serum AMH level is rather inde-
pendent from the hypothalamic pituitary axis and as
such is not modified in pathologies such as hyperprolac-
tinemia, functional hypothalamic amenorrhea or in in-
complete and recent hypogonadotropic hypogonadism,
providing serum FSH level remains normal or sub-
normal [32]. The question thus actually arises about the
replacement of the conventional markers of ovarian re-
serve by the AMH assay [33].
However, serum AMH can be influenced by many
factors and some controversies persist. Obesity is
often associated with a significantly lower level of
serum AMH, but not in all studies [11, 34, 35]. There
is also a controversy regarding the influence of hor-
monal contraception: to some authors, combined
oestrogen progestin does not change AMH serum
levels whereas others have recently reported a de-
crease of 29 to 50 % that could be explained by the
suppression of gonadotropin secretion [36–40]. Simi-
larly a decrease of serum AMH seven days after
injection of depot leuprolide 3.75 mg, a GnRH agon-
ist has been shown [41].
Polycystic Ovary Syndrome (PCOS) and AMH
Definition
Polycystic ovary syndrome (PCOS) is the most common
cause of chronic anovulation and hyperandrogenism in
young women and affects 5 to 10 % of the female popu-
lation [42, 43]. PCOS is a diagnosis of exclusion and is
defined by the Rotterdam classification (2003) [44] re-
quiring at least 2 out of the 3 following characteristics:
(i) cycle disorder, (ii) clinical or biological hyperandro-
genism, (iii) antral follicular excess on ultrasound with ≥
12 follicles from 2 to 9 mm per ovary and/or ovarian
volume ≥ 10 ml. Metabolic disorders are often associated
to PCOS (up to 50 %), including an increased rate of in-
sulin resistance, regardless obesity [45]. PCOS thus im-
poses a considerable economic burden on national
health systems [46]. PCOS is almost certainly a genetic
condition but the precise causes of hyperandrogenism
and anovulation, which are not always associated, are
still under investigations [47, 48].
Pathophysiology
PCOS is characterized by an increased number of folli-
cles at all growing stages [49–51]. This increase is par-
ticularly seen in the pre-antral and small antral follicles,
those which primarily produce AMH [52, 53]. Thus ele-
vated serum AMH level, as a reflection of the stock of
pre antral and small antral follicles, is 2–4 fold higher in
women with PCOS than in healthy women [54–57] and
is found in all PCOS populations [21, 22].
This increase in serum AMH was first thought to be
only due to the higher number of pre antral and small
antral follicles. However, production of AMH by granu-
losa cells was found in vitro to be 75-fold higher in an-
ovulatory PCOS and 20-fold higher in normo ovulatory
PCOS than in normal ovaries [55]. This suggests in-
creased serum AMH levels in PCOS would also reflect
an intrinsic dysregulation of the granulosa cells, in which
AMH, itself, could be involved since an over expression
of the AMH receptor type II (AMHRII) has also been
demonstrated [58, 59].
The cause of such high production of AMH in antral
follicles from PCO is currently unknown, but there is
evidence to support a role played by androgens. Indeed,
a positive correlation between serum androgen and
AMH levels has been reported and the over production
of androgens could be an intrinsic defect of thecal cells
in PCOS [21, 22, 60–62].
Studies demonstrated contradictory results concerning
AMH regulation by gonadotropins. For some authors, go-
nadotropins (especially FSH) inhibit serum AMH produc-
tion in vivo in normal ovaries [63, 64]. Pellat et al. [55]
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also demonstrated a reduced AMH production in
granulosa cells from women with PCOS stimulated by
FSH, but no such effect was found in ‘normal’
women. On the contrary, others demonstrated a
stimulating effect of FSH on AMH expression in nor-
mal ovaries as well as in PCOS [65]. The recent find-
ing that E2 inhibits AMH expression could reconcile
those different results [66]: FSH may directly stimu-
late AMH in small antral follicles, as long as they do
not express aromatase. But in larger follicles, by in-
creasing E2 production with the recruitment of a
dominant follicle, FSH would have an indirect inhibi-
tory effect on AMH expression through the negative
feedback of E2 (Fig. 2).
It has also been demonstrated that AMH signifi-
cantly decreases not only the FSH receptor expression
but also ovarian aromatase expression [18]. This al-
lows protection of the small follicles from premature
aromatase expression. However, when this protective
effect exceeds its physiological role, because of AMH
excess and/or because it lasts longer than it should in
larger follicles, this could result in a defect in the se-
lection of the dominant follicle, thus causing the so
called the “follicular arrest”. The fact that AMH is in-
hibitory to FSH-dependent factors required for follicle
dominance adds considerable significance to the high
serum AMH expression found in PCOS and makes
AMH a putative central actor of the ‘follicular arrest’.
In good agreement, clinical studies have shown a rela-
tionship between high AMH and ovulatory disorder
[55]. Likewise LH seems to stimulate AMH produc-
tion by the granulosa cells in women with PCOS
[55]. Acquisition of LH receptors by the granulosa
cells happens sooner in PCOS [67]. In addition, some
authors demonstrated that LH reduces AMHRII ex-
pression in granulosa luteal cells in normal ovaries
and in women with normo-ovulatory PCOS, whereas
it cannot do so in women with anovulatory PCOS
[65, 68]. Besides LH stimulating effect on AMH ex-
pression, this lack of LH-induced down regulation of
AMHRII expression in women with anovulatory
PCOS could contribute to anovulation. Therefore, the
premature action of LH might also contribute to the
‘follicular arrest’ through a mechanism involving the
AMH system [67, 69].
To sum up, in PCOS, there are many abnormalities of
folliculogenesis: (i) an increased number of small grow-
ing follicles [50], (ii) an inhibition of the terminal follicu-
lar growth [51], resulting in a lack of selection of the
dominant follicle, so-called the “follicle arrest” [70], and
Fig. 2 Schematic diagram of AMH regulation by FSH and E2 in GC of small and large antral follicles. Adapted from Grynberg M et al. JCEM, 2012
[65]. Until the small antral stage, AMH secretion is stimulated by different factors like FSH. Estradiol (E2) production under the influence of FSH is
impaired by the inhibiting effect of AMH on aromatase. When estradiol concentration reaches a certain threshold in large antral follicles, it is
capable of completely inhibiting AMH expression through ERβ, which predominates in growing follicles, thus overcoming the stimulation by FSH.
In large follicles from PCO, the lack of FSH-induced E2 production and the high level of AMH impair the shift form the AMH to the E2 tone, thus
leading to the follicular arrest
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(iii) a follicular apoptosis defect aggravating the excess of
growing follicles [71, 72].
Serum AMH in the diagnosis of PCOS
Given its strong implication in the pathophysiology of
PCOS, serum AMH could be considered the “Gold
Standard” in the diagnosis of PCOS. Even though serum
AMH would be theoretically more accurate than AFC,
as it reflects also the excess of small follicles non-visible
on ultrasound [25, 6, 73] (Fig. 3), it is still considered
premature to make this diagnostic transition.
The robust association between AMH and AFC has
led some authors to compare their performance in the
diagnosis of PCOS [74]. However, the results from the
current literature are not homogeneous [11]. Part of this
heterogeneity is due to the lack of well-defined popula-
tion. In particular, some authors have used the PCOS
definition established in 2003 at the Rotterdam confer-
ence, using 12 follicles of 2–9 mm diameter per ovary
for the polycystic ovaries morphology (PCOM) [75].
This cut off is highly dependent on ultrasound equip-
ment and operator skill, as demonstrated by Dewailly
et al. [76]. Therefore, with the latest ultrasound gen-
eration, the threshold has evolved and is now up to 19 or
25 [73, 77, 78]. This threshold will probably continue to
increase as newer ultrasound technologies and equipment
are developed. Additionally, there are critical issues re-
garding what populations are included or excluded in the
normative population. Lastly, there are technical issues
regarding serum AMH assays leading to further hetero-
geneity of the results in the literature.
It is therefore impossible, so far, to propose a consen-
sual and universal diagnostic threshold for serum AHM
in the prediction of PCOS. However, in our experience,
a cut off at 35 pmol/L (4.9 ng/mL) with the enzyme im-
munoassay AMH-EIA (EIA AMH/MIS kit) (“Immuno-
tech”, ref A16507) provided by Beckman Coulter
(France) had a good specificity (97 %) and a better sensi-
tivity than the AFC (92 %) to distinguish women with
PCOS from normal women [73]. This result was ob-
tained after exclusion of women with asymptomatic
PCO from the control group through cluster analysis, a
mathematical procedure that avoids using predefined
thresholds for AMH and AFC. This approach has been
replicated in another setting [77]. Pigny et al. (unpub-
lished data) have also compared the five serum AMH as-
says (as described above) for the diagnosis of PCOS.
They proposed, with manual ELISAs assays, a higher
cut-off at 5.6 ng/mL (40 pmol/L), as biological criteria
indicative of PCOM, corresponding to the 95th percent-
ile of “pure” controls. They also proposed a threshold at
4.2 ng/mL (30 pmol/L) for the automatic assays (unpub-
lished data). If confirmed with the new automatized
serum AMH assays or the ultrasensitive assay, a high
serum AMH level could then become a reliable and ac-
curate marker for PCOM, and eventually replace the
AFC, which also suffers from great controversy in the
literature. As an ‘increased serum AMH’ does not refer
to ovarian morphology, the acronym ‘PCOM’ would not
be appropriate and we have therefore suggested the term
“PCO-like abnormality” (i.e., PCOM and/or increased
serum AMH) as the third item of the Rotterdam classifi-
cation rather than ‘PCOM’ [79, 74].
Serum AMH level is also correlated to the severity of
PCOS symptoms [68] and is higher when hyperandrogen-
ism [62, 80] or oligo-anovulation is present [21, 55, 81]. By
a principal component analysis, it has been shown a high
serum AMH level can be considered as a marker of
Fig. 3 Rationale for the use of serum AMH assay as a probe for PCOM. Dewailly, D., et al., Hum Reprod Update, 2014 [24]. a All growing follicles
secrete AMH but serum AMH reflects only the secretion from bigger follicles that are in contact with the vascular bed. As the numbers of follicles
in all growth stages are strongly related to each other, serum AMH is considered to reflect the sum of growing follicles but not the number of
primordial follicles that do not secrete AMH. b In PCO, the numbers of all growing follicles is increased, resulting in a marked increase in serum
AMH level. AMH may be considered as a deeper and more sensitive probe to define follicle excess than the follicle count by ultrasound (U/S)
since it appraises more follicle classes (blue arrows)
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hyperandrogenism and could also be used as a substitute
for this item in the Rotterdam classification [82].
This would reconcile the different classifications cur-
rently available for PCOS because some require hyper-
androgenism as a necessary criterion [56]. We thus
propose the following strategy: for the diagnosis of
PCOS, hyperandrogenism and oligo anovulation should
be first sought, after excluding all alternative diagnoses.
If one is missing, a high AFC or/and AMH level could
be used instead.
In adolescent and young women with PCOS, it is
sometimes difficult to evaluate the ovaries on ultrason-
ography. It can also be difficult to estimate the share of
the physiological and pathological, concerning acne and
cycle disorders. Serum AMH assay is therefore a true al-
ternative, as it is recommended by the American associ-
ation of clinical endocrinologists [83]. Adolescents with
PCOS have higher serum AMH levels, with a thresholds
set at 30 pmol/L [84], which is in the range of values
found in the literature for older PCOS women [85, 86].
However, it must be noticed that the thresholds for ex-
cessive AFC or high serum AMH level have to be
reviewed and validated worldwide, since recent technical
developments in ultrasound and assays could lead to
their modification. In the meantime, it is recommended
that each centre set its own thresholds.
THE use of serum AMH for the treatment of PCOS
AMH: useful in treatments of infertility?
Because of the dysovulation often associated, PCOS is a
frequent cause of infertility. The follicular excess present
in this pathology can be responsible for an ovarian over-
response when induction ovulation treatments are used
increasing risk for ovarian hyperstimulation syndrome
(OHSS). This is a challenging situation as the minimal
effective dose is often very close to the overdose leading
to hyperstimultation.
Thus, in addition to its diagnostic role, serum AMH
level is useful to establish treatment protocols and to de-
fine the best strategy for ovulation induction in infertile
women with PCOS.
Clomiphene citrate
So far, there are very few studies that have examined the
predictive power of serum AMH level in the response to
clomiphene citrate (CC). Mahran et al. [87] have pro-
posed a threshold at 3.4 ng/mL above which a resistance
to CC is highly expected, suggesting a higher starting
dose should be used. However, the free androgen index
was significantly higher among the non-responding pa-
tients which may have biased the results since this par-
ameter is a well-known negative predictor. Also the
sensitivity and specificity were poor (around 75 %),
leading to wrong information in ¼ of cases, making diffi-
cult the use of this threshold in clinical practice.
Recombinant FSH
Serum AMH level appears to be a good predictive
marker for the risk of OHSS [88], mostly occurring in
PCOS, as proved in the meta-analysis of Broer et al. [89].
However the establishment of an accurate threshold re-
mains difficult because of the heterogeneity of the OHSS
definition and technical issues with the AMH assays.
To conclude, serum AMH determination may be a
helpful tool in the prediction of the ovarian response to
gonadotropins in PCOS. Difficulties persist, however,
since there is no consensus on the threshold for the
AMH values. This is due to the well-known difficulty of
quantification and standardization of the AMH assays.
Ovarian drilling
Laparoscopic ovarian drilling (LOD) is currently recom-
mended as a successful second line treatment for ovula-
tion induction in women with PCOS. It is considered to
be an alternative to gonadotropin stimulation in the case
of CC resistance [90].
The aim is to trigger spontaneous ovulation by
destroying small amounts of ovarian cortex. The physio-
logical mechanism remains unknown, but drilling sig-
nificantly alters the hormonal environment within the
ovary. The utility of the AMH assay as a predictor for
LOD outcome has been recently questioned [91]. Two
studies evaluated serum AMH before LOD to correlate
with the results in terms of spontaneous ovulation
[92, 93]. Elsmashad et al. [92] evaluated the effect of
LOD, in PCOS, on serum AMH and ovarian stromal
blood flow changes, by using three-dimensional power
Doppler ultrasonography. They showed LOD was
followed by lower serum AMH levels and less ele-
vated Doppler flow indices. Amer et al. [93] also
showed that women who ovulated after LOD had
lower pre-operative AMH levels. They identified a
pretreatment AMH level cut-off of 7.7 ng/mL (sensi-
tivity 78 %, specificity 76 %), which predicted failure
of LOD. Weaknesses of this study included the small
sample size and the fact LOD was used as a first line
method for ovulation induction
AMH: a marker of treatment efficiency on PCOS
symptoms?
To normalize the menstrual cycle, it is common to pre-
scribe a hormonal contraception to women with PCOS.
As explained above, there is, however, controversy re-
garding the impact of hormonal contraception on the
AMH circulating level [6, 38]. In PCOS, it has recently
been shown [94] that in current users of hormonal
contraception, SHBG was increased, leading to a
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diminished bioavailable androgen level, and that AMH
and AFC levels were decreased. However, no study has
reported so far this decrease of serum AMH has a pre-
dictive value on the subsequent fertility.
To have an anti-androgenic effect and thus decrease
the clinical hyperandrogenism (such as acne, hirsutism)
it is common, in PCOS, to use oral combined contracep-
tive treatment sometimes combined with antiandrogens
such as drospirenone or cyproterone acetate (CPA) or
spironolactone [95, 96]. Panidis et al. [97] have shown a
significant decrease in serum AMH levels in women
with PCOS with ethinylestradiol + CPA but not with use
of ethinylestradiol + drospirenone.
Some studies have evaluated the relationship between
weight loss, menstrual cyclicity and serum AMH levels
in overweight women with PCOS. Moran et al. [98]
showed better menstrual improvement after weight loss
in women with lower baseline serum AMH. Serum
AMH could therefore be used as a potential predictive
factor of cycle normalization after weight loss. Nybacka
et al. [99] described a significant decrease in serum
AMH levels after diet in obese women with PCOS.
Thomson et al. [100] demonstrated long-term weight
loss (twenty weeks) resulted in improvements in repro-
ductive function but did not change serum AMH levels.
Lastly, various effects on AMH level were obtained with
Metformin usage in women with PCOS [97, 101–104].
Altogether, no threshold for serum AMH can be pro-
posed to predict the effectiveness of these treatments.
Conclusion
It is now undeniable that serum AMH is a valuable tool
for the diagnosis of PCOS. As for its benefit in the treat-
ment of PCOS, there may be an advantage in therapeutic
decision support, but this needs to be confirmed by fur-
ther studies. However, the current technical difficulties
to set up consensual serum AMH thresholds [105, 19]
(stability and heterogeneity of circulating AMH, wide
range of values, inter laboratory variability, different im-
munoassays used worldwide) may have curbed the en-
thusiasm of some clinicians to make it “THE” marker of
PCOM. However, we must remain optimistic regarding
the latest progress made, making it more and more real-
istic that this assay may, one day, replace the AFC in the
Rotterdam classification.
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